WO2005012273A2 - Process for the preparation of substituted thiazoles - Google Patents
Process for the preparation of substituted thiazoles Download PDFInfo
- Publication number
- WO2005012273A2 WO2005012273A2 PCT/US2004/024758 US2004024758W WO2005012273A2 WO 2005012273 A2 WO2005012273 A2 WO 2005012273A2 US 2004024758 W US2004024758 W US 2004024758W WO 2005012273 A2 WO2005012273 A2 WO 2005012273A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solvent
- temperature
- group
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Definitions
- TEI-6720 The compound ethyl 2-(4-hydroxyphenyl)-4-methyl-l,3-thiazole-5-carboxylate, also known as TEI-6720, is useful for treatment of gout and hyperuricemia.
- This compound belongs to a class of substituted thiazoles that inhibit xanthine oxidase and thus block uric acid production.
- the synthesis of TEI-6720 involves two steps. In the first step, an aryl nitrile is converted to a thioamide. In the second step the thioamide is converted to a thiazole. Because of the therapeutic usefulness of TEI-6720 there is sustained interest in improving the synthesis of substituted thiazoles in general and TEI-6720 in particular.
- R is selected from the group consisting of hydrogen, Ci-C ⁇ -alkyl, C 2 -C 6 - alkenyl, and C 2 -C 6 -alkynyl; and R 3 is selected from the group consisting of hydrogen, Ci-C ⁇ -alkyl, C 2 -C 6 -alkenyl, and C 2 - C 6 -alkynyl.
- a second embodiment of this invention is directed to a process for making the compound of formula (TV), the process comprising: (b) reacting the compound having formula (I) and a compound having formula (V)
- This invention discloses a novel process for isolating thioamides, key intermediates in the synthesis of TEI-6720.
- the isolation of the thioamide intermediate allows for cleaner synthesis of the thiazole and avoids the aqueous workup that was formerly required.
- the invention discloses a synthesis that eliminates the need for a catalyst, yet decreases processing time and increases the product yield.
- this invention allows large-scale synthesis and a commercially feasible process for making TEI-6720.
- DEFINITION OF TERMS As used throughout this specification and the appended claims, the following terms have the following meanings: All of the processes of the instant invention can be conducted as continuous processes.
- alkenyl as used herein, means a straight or branched chain hydrocarbon containing from 2 to 6 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens.
- Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, and 5-hexenyl.
- alkyl as used herein, means a straight or branched chain hydrocarbon containing from 1 to 6 carbon atoms.
- alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl.
- alkynyl as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 6 carbon atoms and containing at least one carbon-carbon triple bond.
- alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2- propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
- aryl as used herein, means a phenyl group, or a bicyclic or a tricyclic fused ring system wherein one or more of the fused rings is a phenyl group.
- Bicyclic fused ring systems are exemplified by a phenyl group fused to a cycloalkyl group, as defined herein, or another phenyl group.
- Tricyclic fused ring systems are exemplified by a bicyclic fused ring system fused to a cycloalkyl group, as defined herein, or another phenyl group.
- Representative examples of aryl include, but are not limited to, anthracenyl, azulenyl, fluorenyl, indanyl, indenyl, naphthyl, phenyl and tetrahydronaphthyl.
- heteroaryl refers to an aromatic five- or six-membered ring wherein 1, 2, 3, or 4 heteroatoms are independently selected from N, O, or S. The five membered rings have two double bonds and the six membered rings have three double bonds.
- heteroaryl groups are connected to the parent molecular moiety through a carbon or nitrogen atom.
- heteroaryl also includes bicyclic systems where a heteroaryl ring is fused to a phenyl group, a monocyclic cycloalkyl group, as defined herein, a heterocycle group, as defined herein, or an additional heteroaryl group; and tricyclic systems where a bicyclic system is fused to a phenyl group, a monocyclic cycloalkyl group, as defined herein, a heterocycle group, as defined herein, or an additional heteroaryl group.
- heteroaryl include, but are not limited to, benzothienyl, benzoxadiazolyl, cinnolinyl, dibenzofuranyl, fiiropyridinyl, furyl, imidazolyl, indazolyl, indolyl, isoxazolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, quinolinyl, tetrazolyl, thiadiazolyl, thiazolyl, thienopyridinyl, thienyl, triazolyl, and triazinyl.
- bases represents a reagent capable of accepting protons during the course of a reaction.
- bases include carbonate salts such as potassium carbonate, potassium bicarbonate, sodium carbonate, sodium bicarbonate, and cesium carbonate; halides such as cesium fluoride; phosphates such as potassium phosphate, potassium dihydrogen phosphate, and potassium hydrogen phosphate; hydroxides such as lithium hydroxide, sodium hydroxide, and potassium hydroxide; disilylamides such as lithium hexamethyldisilazide, potassium hexamethyldisilazide, and sodium hexamethyldisilazide; trialkylamines such as triethylamine, diisopropylamine, and diisopropylethylamine; heterocyclic amines such as imidazole, pyridine, pyridazine, pyrimidine, and pyrazine; bicyclic amines such as DBN and DBU; and
- solvent refers to the dispersing medium of a solution.
- solvents include, C 2 -C 5 alkylamides such as formaldehyde, N,N- dimethylformamide, N,N-dimethylacetamide, and the like; C 4 -C 6 dialkoxyalkyls such as DME, 1 ,2-diethoxyethane, and the like; C ⁇ -C 4 alcohols such as methanol, ethanol, propanol, iso- propanol, butanol, iso-butanol, sec-butanol, tert-butanol, and the like; C 3 -C ⁇ o ketones such as acetone, 2-butanone, 3-pentanone, 2-butanone, 2-pentanone, 2,5-heptanedione,
- alkoxyalkyl as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
- Representative examples of alkoxyalkyl include, but are not limited to, tert-butoxymethyl, 2- ethoxyethyl, 2-methoxyethyl, and methoxymethyl. Percentages such as % yield were obtained by HPLC analyses of starting materials and products. Values were calculated from the peak area.
- conversion of compounds of formula (II) to compounds of formula (I) can be achieved by reaction of the former with H 2 S and a base in a solvent.
- the base is a compound having formula (III) (M) + (YH)- (III), in which M is sodium, potassium, lithium, or ammonium and Y is oxygen or sulfur.
- the reaction generally proceeds under a pressure of at least 10 psi and at a temperature of about 0°C to about 150°C for about 15 minutes to several days depending on the temperature and nature of the reactants. In a preferred embodiment this conversion is achieved at a pressure of 60 psi, a temperature of 70°C, and in a solvent of water.
- Conversion of compounds of formula (I) to compounds of formula (IV) can be achieved by reacting compounds of formula (I) with compounds of formula (V) in a solvent.
- the reaction generally proceeds at a temperature of about 0°C to about 150°C for about 15 minutes to several days depending on the temperature and nature of the reactants. In a preferred embodiment this conversion is achieved at a temperature of 80°C and in a solvent of ethanol.
- 4-hydroxybenzene carbothioamide (a compound of formula (I)) is prepared by reacting 4-hydroxybenzonitrile (a compound of formula (II)), H 2 S, and sodium hydrogen sulfide (a base and compound of formula (III)) under a pressure of at least 10 psi at a temperature of about 0°C to about 150°C in a solvent.
- the pressure is 60 psi
- the temperature is 70°C
- the solvent is water.
- ethyl 2-(4 hydroxyphenyl)-4-methyl-l, 3- thiazole-S-carboxylate (a compound of formula (IV)) is prepared by reacting 4-hydroxybenzene carbothiomide (a compound of formula (I)) with ethyl-2-chloroacetoacetate (a compound of formula (V)) at a temperature of about 0°C to about 150°C in a solvent.
- the temperature is 80°C and the solvent is ethanol.
- ethyl 2-(4 hydroxyphenyl)-4-methyl-l, 3- thiazole-S-carboxylate (a compound of formula (IV)) is prepared by:
- step (b) reacting the product of step (a) and ethyl-2-chloroacetoacetate at a temperature of about 0°C to about 150°C in a solvent.
- the pressure is 60 psi
- the temperature is 70°C
- the solvent is water.
- the temperature is 80°C and the solvent is ethanol.
- the pressure is 60 psi
- the temperature is 70°C
- the solvent is ethanol.
- the temperature is 80°C and the solvent is ethanol.
- Example 1 4-hydroxybenzene carbothioamide
- 4-Cyanophenol 50.0 g, 0.42mol
- NaSH 15.5g, .21mol
- distilled water 125mL
- the mixture was then put under a vacuum, flushed with H 2 S, and the pressure was brought to 40-50 psi for a period of a few minutes.
- the mixture was then heated to 70°C and stirred for 40-45 minutes.
- the mixture was stirred vigorously at 70°C under constant pressure of 56 psi for 5 hours and 15 minutes.
- the H 2 S pressure was removed and the reaction was cooled to room temperature.
- the reaction was neutralized to pH 5-7 with 2 M HC1 (66 mL).
- the product was filtered, and the filter cake washed with distilled water (2x50 mL), and dried under a vacuum at 80-85°C for 22 hours to provide 62.74 g (97.57%) desired product.
- Example 2 Ethyl 2-(4-hydroxyphenyl " )-4-methyl-l .3-thiazole-5-carboxylate A mixture of 4-Cyanophenol (23.82 g, 0.2mol), NaOH (8g, .2mol), and 200 mL ethanol were mixed in a pressure bottle while heated to 80°C. Hydrogen sulfide gas was then introduced and the pressure increased to 30-60 psi until the thioamidation was determined to be complete by HPLC. Without isolating the thioamide product, HC1 was added to the bottle until the pH was below 3.5, the H 2 S gas was removed, and the bottle was placed under a vacuum for 20 minutes at 30-40°C.
- reaction was then heated to 70°C and ethyl 2-chloroacetoacetate(l.l eq.) was added to the reaction solution.
- the reaction was mixed under reflux for 2-3 hours, treated with enough H 2 O to dissolve the NaCl salt in the reaction mixture, cooled to room temperature, treated with enough water to precipitate the product, and the solid was collected by filtration.
- the precipitate was washed with water and dried at 80°C with nitrogen bleeding to provide 50.50 g (84.2%) of desired product.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HK06111923.3A HK1093725B (en) | 2003-07-30 | 2004-07-30 | Process for the preparation of substituted thiazoles |
| EP04779726.1A EP1651624B1 (en) | 2003-07-30 | 2004-07-30 | Process for the preparation of substituted thiazoles |
| MXPA06001201A MXPA06001201A (es) | 2003-07-30 | 2004-07-30 | Proceso para la preparacion de tiazoles substituidos. |
| JP2006522112A JP4975435B2 (ja) | 2003-07-30 | 2004-07-30 | 置換されたチアゾールの製造方法 |
| CA2533658A CA2533658C (en) | 2003-07-30 | 2004-07-30 | Process for the preparation of substituted thiazoles |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/630,043 | 2003-07-30 | ||
| US10/630,043 US20050027128A1 (en) | 2003-07-30 | 2003-07-30 | Substituted thiazoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2005012273A2 true WO2005012273A2 (en) | 2005-02-10 |
| WO2005012273A3 WO2005012273A3 (en) | 2005-05-12 |
Family
ID=34103748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2004/024758 Ceased WO2005012273A2 (en) | 2003-07-30 | 2004-07-30 | Process for the preparation of substituted thiazoles |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050027128A1 (enExample) |
| EP (2) | EP2386548A2 (enExample) |
| JP (1) | JP4975435B2 (enExample) |
| CA (1) | CA2533658C (enExample) |
| MX (1) | MXPA06001201A (enExample) |
| WO (1) | WO2005012273A2 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010143735A1 (ja) | 2009-06-09 | 2010-12-16 | 帝人ファーマ株式会社 | 4-置換ベンゾチオアミド誘導体の製造法 |
| WO2011073617A1 (en) | 2009-12-14 | 2011-06-23 | Cipla Limited | Processes for the preparation of febuxostat and salts thereof |
| CN102702054A (zh) * | 2012-06-29 | 2012-10-03 | 晋城海斯制药有限公司 | 一种对羟基硫代苯甲酰胺的制备方法 |
| CN104610110A (zh) * | 2014-03-12 | 2015-05-13 | 广东东阳光药业有限公司 | 一种制备4-取代硫代苯甲酰胺衍生物的方法 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9221914B2 (en) * | 2007-12-26 | 2015-12-29 | Biotest Ag | Agents targeting CD138 and uses thereof |
| CA2725047A1 (en) * | 2008-05-22 | 2009-11-26 | Bristol-Myers Squibb Company | Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same |
| US8857343B2 (en) * | 2012-05-29 | 2014-10-14 | Liberty Ammunition, Llc | High volume multiple component projectile assembly |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3518279A (en) * | 1967-08-29 | 1970-06-30 | American Cyanamid Co | Thiazolylphenyl phosphates |
| US3852287A (en) * | 1970-03-26 | 1974-12-03 | Uniroyal Ltd | Preparation of thionamides |
| US4528291A (en) * | 1982-06-22 | 1985-07-09 | Schering Corporation | 2-(4'-Pyridinyl)-thiazole compounds and their use in increasing cardiac contractility |
| DE4031804A1 (de) * | 1990-10-08 | 1992-04-09 | Basf Ag | Indophenolfarbstoffe und ein verfahren zu ihrer thermischen uebertragung |
| CA2073981C (en) * | 1990-11-30 | 2002-01-08 | Shiro Kondo | 2-arylthiazole derivatives and pharmaceutical composition thereof |
| JP2706037B2 (ja) * | 1993-04-13 | 1998-01-28 | 帝人株式会社 | シアノ化合物およびその製造方法 |
| JPH10139770A (ja) * | 1996-11-08 | 1998-05-26 | Teijin Ltd | 2−(3−シアノフェニル)チアゾール誘導体の製造法 |
| JP3440196B2 (ja) * | 1997-08-13 | 2003-08-25 | 帝人株式会社 | チオベンズアミド誘導体の製造方法 |
| DE19934066A1 (de) * | 1999-07-23 | 2001-01-25 | Basf Ag | Verfahren zur Herstellung von 4-Cyano-2-aminomethylthiazol |
| PE20011010A1 (es) * | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
| JP4716547B2 (ja) * | 2000-08-10 | 2011-07-06 | 住友精化株式会社 | 2−フェニルチアゾール類の製造方法 |
| JPWO2002079177A1 (ja) * | 2001-03-29 | 2004-07-22 | 日本曹達株式会社 | (4−フェニルチアゾール−2−イル)アルカンニトリルの製造方法 |
| JP2003002863A (ja) * | 2001-06-25 | 2003-01-08 | Nippon Soda Co Ltd | 安息香酸類の製造方法および新規化合物 |
-
2003
- 2003-07-30 US US10/630,043 patent/US20050027128A1/en not_active Abandoned
-
2004
- 2004-07-30 JP JP2006522112A patent/JP4975435B2/ja not_active Expired - Lifetime
- 2004-07-30 CA CA2533658A patent/CA2533658C/en not_active Expired - Fee Related
- 2004-07-30 EP EP11170183A patent/EP2386548A2/en not_active Withdrawn
- 2004-07-30 EP EP04779726.1A patent/EP1651624B1/en not_active Expired - Lifetime
- 2004-07-30 WO PCT/US2004/024758 patent/WO2005012273A2/en not_active Ceased
- 2004-07-30 MX MXPA06001201A patent/MXPA06001201A/es active IP Right Grant
Non-Patent Citations (1)
| Title |
|---|
| None |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010143735A1 (ja) | 2009-06-09 | 2010-12-16 | 帝人ファーマ株式会社 | 4-置換ベンゾチオアミド誘導体の製造法 |
| EP2441752A4 (en) * | 2009-06-09 | 2012-11-21 | Teijin Pharma Ltd | PROCESS FOR PRODUCING A 4-SUBSTITUTED BENZOTHIOAMIDE DERIVATIVE |
| WO2011073617A1 (en) | 2009-12-14 | 2011-06-23 | Cipla Limited | Processes for the preparation of febuxostat and salts thereof |
| CN102702054A (zh) * | 2012-06-29 | 2012-10-03 | 晋城海斯制药有限公司 | 一种对羟基硫代苯甲酰胺的制备方法 |
| CN104610110A (zh) * | 2014-03-12 | 2015-05-13 | 广东东阳光药业有限公司 | 一种制备4-取代硫代苯甲酰胺衍生物的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4975435B2 (ja) | 2012-07-11 |
| HK1093725A1 (en) | 2007-03-09 |
| WO2005012273A3 (en) | 2005-05-12 |
| JP2007500724A (ja) | 2007-01-18 |
| EP2386548A2 (en) | 2011-11-16 |
| MXPA06001201A (es) | 2006-05-15 |
| US20050027128A1 (en) | 2005-02-03 |
| EP1651624B1 (en) | 2015-03-11 |
| CA2533658C (en) | 2013-10-22 |
| CA2533658A1 (en) | 2005-02-10 |
| EP1651624A2 (en) | 2006-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7216704B2 (ja) | アミノピリミジン誘導体の合成に有用な新規中間体、それを調製するためのプロセス、及びそれを使用してアミノピリミジン誘導体を調製するためのプロセス | |
| US7541475B2 (en) | Substituted thiazoles | |
| CA2533658C (en) | Process for the preparation of substituted thiazoles | |
| JPS6045621B2 (ja) | ブタノン誘導体の製造方法 | |
| EP0653421B1 (en) | Process for preparing 2-cyanoimidazole compounds | |
| HK1163101A (en) | Preparation of thioamides | |
| EP3137462B1 (en) | Processes and intermediates for the preparation of a pde10 inhibitor | |
| AU2001287699A1 (en) | Continuous process for the preparation of pesticidal chlorothiazoles | |
| EP1311494A1 (en) | Continuous process for the preparation of pesticidal chlorothiazoles | |
| HK1093725B (en) | Process for the preparation of substituted thiazoles | |
| JP2004506725A (ja) | 触媒作用下におけるチアゾール誘導体の製法 | |
| JP2013067602A (ja) | α−ヒドロキシケトン化合物の製造方法 | |
| JPH04330056A (ja) | 2−クロロ−5−メチル−ピリジンの製造方法 | |
| HU229503B1 (en) | Process for the manufacture of thiazole derivatives with pesticidal activity | |
| JP2010132593A (ja) | 4−アルキルレゾルシノールの製造方法 | |
| CET? N et al. | Transfer Hydrogenation of Acetophenone Catalyzed by in situ Generated 2, 6‐Bis (5‐thioxo‐4, 5‐dihydro‐1, 2, 4‐triazole‐3‐yl) pyridine‐ruthenium (II) Complexes | |
| CN117362142B (zh) | 环己烯衍生物的不对称催化氢化方法 | |
| JP5064872B2 (ja) | N−(2−アミノ−1,2−ジシアノビニル)イミデート類の製造方法 | |
| CN108929304B (zh) | 一种反式2-取代基-5-羧基-1,3-二氧六环的制备方法 | |
| KR20170080190A (ko) | 1,5-쌍극자의 [5+3] 고리화 첨가 반응을 이용한 8원 헤테로 고리 화합물의 제조 방법 및 이에 의해 제조된 8원 헤테로 고리 화합물 | |
| TWI261054B (en) | Process for the preparation of 1,3-disubstituted 2-nitroguanidines | |
| JP4353801B2 (ja) | 1−(ピリミジン−2−イル)プロパン−2−オン類の製造方法 | |
| JPS62242662A (ja) | N−アミノフタルイミドの改良合成法 | |
| JPS61200978A (ja) | 3−置換アミノ−1,3−チアゾリジン−2,4−ジオン誘導体及びその製造法 | |
| JPH04211030A (ja) | 光学活性アルコールの製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| ENP | Entry into the national phase |
Ref document number: 2533658 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006522112 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/001201 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2004779726 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004779726 Country of ref document: EP |